Dr. Todd Morgan

So it's really sort of the radiation field. Is it just prostate bed or prostate bed plus nodes? And then I guess even prostate bed plus nodes plus or minus metastasis directed therapy if there are a couple other sites of disease seen on PSMA PET. So that's really, that's the radiation piece. And then there's ADT and there's timing of or length of ADT.

So it's really sort of the radiation field. Is it just prostate bed or prostate bed plus nodes? And then I guess even prostate bed plus nodes plus or minus metastasis directed therapy if there are a couple other sites of disease seen on PSMA PET. So that's really, that's the radiation piece. And then there's ADT and there's timing of or length of ADT.

Time that we give ADT, minimum of four to six months for patients who are getting ADT, but 18 to 24 months recommended for patients with high-risk features who are undergoing RT. And then on top of that, there's ongoing research into intensification. And so meaning intensified hormone therapy, like adding enzalutamide or apalutamide.

Time that we give ADT, minimum of four to six months for patients who are getting ADT, but 18 to 24 months recommended for patients with high-risk features who are undergoing RT. And then on top of that, there's ongoing research into intensification. And so meaning intensified hormone therapy, like adding enzalutamide or apalutamide.

Time that we give ADT, minimum of four to six months for patients who are getting ADT, but 18 to 24 months recommended for patients with high-risk features who are undergoing RT. And then on top of that, there's ongoing research into intensification. And so meaning intensified hormone therapy, like adding enzalutamide or apalutamide.

And so that data is still basically immature in TBD, but clinical trials evaluating whether that might also be beneficial. And then there's the timing of when do we actually start initiating these steps.

And so that data is still basically immature in TBD, but clinical trials evaluating whether that might also be beneficial. And then there's the timing of when do we actually start initiating these steps.

And so that data is still basically immature in TBD, but clinical trials evaluating whether that might also be beneficial. And then there's the timing of when do we actually start initiating these steps.

Yeah.

Yeah.

Yeah.

You're thinking like Decipher or Terra or something else?

You're thinking like Decipher or Terra or something else?

You're thinking like Decipher or Terra or something else?

Presented some data at the AUA this year on using Arteria classifier. I think not everybody, probably not everybody knows what it is. Although just I think today, yesterday, it was named in Time Magazine as the medical invention of the year. So that's kind of huge props to that team led by Andrea Esteva and Felix Fang.

Presented some data at the AUA this year on using Arteria classifier. I think not everybody, probably not everybody knows what it is. Although just I think today, yesterday, it was named in Time Magazine as the medical invention of the year. So that's kind of huge props to that team led by Andrea Esteva and Felix Fang.

Presented some data at the AUA this year on using Arteria classifier. I think not everybody, probably not everybody knows what it is. Although just I think today, yesterday, it was named in Time Magazine as the medical invention of the year. So that's kind of huge props to that team led by Andrea Esteva and Felix Fang.

What it is is basically digital pathology-driven AI multimodal learning to input patients' clinical features and the images from their histology can be biopsy, can be prostatectomy, and then output, just like the cipher, prognostic information like risk of metastasis. So Otero's model uses the digital pathology images along with the clinical information.

What it is is basically digital pathology-driven AI multimodal learning to input patients' clinical features and the images from their histology can be biopsy, can be prostatectomy, and then output, just like the cipher, prognostic information like risk of metastasis. So Otero's model uses the digital pathology images along with the clinical information.

What it is is basically digital pathology-driven AI multimodal learning to input patients' clinical features and the images from their histology can be biopsy, can be prostatectomy, and then output, just like the cipher, prognostic information like risk of metastasis. So Otero's model uses the digital pathology images along with the clinical information.